Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
96.67 INR | +1.24% | +3.00% | -28.84% |
May. 21 | Transcript : Camlin Fine Sciences Limited, Q4 2024 Earnings Call, May 21, 2024 | |
May. 20 | Camlin Fine Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.84% | 192M | - | ||
+21.26% | 68.69B | A- | ||
-0.07% | 49.19B | A- | ||
+24.11% | 44.73B | B+ | ||
+30.30% | 28.24B | A- | ||
+7.64% | 19.22B | C+ | ||
+10.10% | 16.68B | B+ | ||
-5.26% | 16.08B | B+ | ||
-23.26% | 15.62B | A- | ||
-18.20% | 13.89B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CAMLINFINE Stock
- Ratings Camlin Fine Sciences Limited